Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage in El Salvador
El Salvador: Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage was 96.0% in 2024. ▲ Rising
Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage in El Salvador, 2010–2024
Source: WHO & UNICEF (2025); UN, World Population Prospects (2024) – processed by Our World in Data. Measured in %.
Analysis
El Salvador recorded 96.0% for pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage in 2024.
Compared with earlier readings it is down 3.0% on the previous year and up 9.1% over ten years.
Over the whole period, pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage in El Salvador peaked at 99.0% in 2015 and was at its lowest, 66.0%, in 2010.
El Salvador ranks 15th of 146 countries on this measure, in the top 10%.
The long-run direction has been consistently rising across the 15 years of available data.
Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage in El Salvador, year by year
| Year | % | Change |
|---|---|---|
| 2010 | 66.0% | — |
| 2011 | 95.0% | +43.9% |
| 2012 | 94.0% | -1.1% |
| 2013 | 92.0% | -2.1% |
| 2014 | 88.0% | -4.3% |
| 2015 | 99.0% | +12.5% |
| 2016 | 97.0% | -2.0% |
| 2017 | 96.0% | -1.0% |
| 2018 | 87.0% | -9.4% |
| 2019 | 96.0% | +10.3% |
| 2020 | 93.0% | -3.1% |
| 2021 | 92.0% | -1.1% |
| 2022 | 90.0% | -2.2% |
| 2023 | 99.0% | +10.0% |
| 2024 | 96.0% | -3.0% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2010s | 91.0% | 66.0% | 99.0% | 10 |
| 2020s | 94.0% | 90.0% | 99.0% | 5 |
Countries ranked near El Salvador
More health data for El Salvador
- Un projection of annual infant deaths, annual growth rate -1.89 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.4574 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,537 deaths per 1,000 people (2090)
- Number of infants who die before age 1 104 deaths (2100)
- Population ages 60-64, female, annual growth rate 2.95 % change on previous year (2025)
- Population ages 60-64, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 60-64, female, per capita 0.0214 units per person (2025)
- Population ages 60-64, male, annual growth rate 2.32 % change on previous year (2025)
- Population ages 60-64, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 60-64, male, per capita 0.0142 units per person (2025)
Frequently asked questions
- What is pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage in El Salvador?
- Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage in El Salvador was 96.0% in 2024, according to WHO & UNICEF (2025); UN, World Population Prospects (2024) – processed by Our World in Data.
- What is the highest pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage recorded in El Salvador?
- The highest recorded value was 99.0% in 2015.
- What is the lowest pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage recorded in El Salvador?
- The lowest recorded value was 66.0% in 2010.
- How does El Salvador rank for pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage?
- El Salvador ranks 15th out of 146 countries with data for 2024.
- Is pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage rising or falling in El Salvador?
- Over the last ten years it is up 9.1%. The long-run trend across the full record is rising.
- Where does this El Salvador data come from?
- The figures come from WHO & UNICEF (2025); UN, World Population Prospects (2024) – processed by Our World in Data, published as part of Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 15 observations, free to reuse under CC BY 4.0 (Our World in Data).
About this data
Share of one-year-olds who have had the third dose of the pneumococcal conjugate vaccine in a given year.